Company news

PolyNovo Limited news in 2016

PolyNovo Limited's news releases, calls and decks from 2016, newest first.

View company

Operational Update and Financial Result Guidance

February 10, 2016

NovoSorb Hernia Repair Feasibility Agreement

February 10, 2016

NovoSorb BTM Proof of Concept in Man Achieved

February 10, 2016

NovoSorb BTM Burn Trial

February 10, 2016

New Chief Executive Officer and Head of Regulatory Affairs

February 10, 2016

New Applications for AOD9604

February 10, 2016

Metabolic`s Osteoporosis Patent Allowed in US

February 10, 2016

Metabolic Licenses AOD9604

February 10, 2016

Metabolic Commences Seeking Partners for Bone Applications

February 10, 2016

Half Year Report and Accounts

February 10, 2016

Half Year Financial Result Guidance

February 10, 2016

Full Year Statutory Accounts

February 10, 2016

First Human Study for PolyNovos Novosorb

February 10, 2016

Final Patient Treated in NovoSorb BTM Clinical Trial

February 10, 2016

Final Patient Recruited in Adelaide Burn Trial

February 10, 2016

Dr Stewart Washer joins Calzada as CEO

February 10, 2016

Czd: phosphagenics exercises option to licence AOD9604

February 10, 2016

CZD: Calzada to vend Metabolic into ATOS Wellness

February 10, 2016

CZD: Calzada signs Licensing deal with Phosphagenics

February 10, 2016

CZD: Calzada sells Avexa Shares

February 10, 2016

Clinical Paper on Patient follow up of PolyNovo BTM

February 10, 2016

Changes to Executive Structure

February 10, 2016

CE Mark Clinical Trial for BTM in Severe Burns

February 10, 2016

Calzada Update on Metabolic Pharmaceuticals

February 10, 2016

Calzada Transfers Neural Regeneration Peptides Technology

February 10, 2016

Calzada to Divest Metabolic

February 10, 2016

Calzada moves to 100% ownership of PolyNovo

February 10, 2016

BTM safety studies update

February 10, 2016

Biomet and PolyNovo mutually terminate Development and Licen

February 10, 2016

Appointment of Chief Executive Officer

February 10, 2016

Appendix 4E and 2012 Annual Report

February 10, 2016

Appendix 4E and 2011 Annual Report

February 10, 2016

App 4E / Full Year Statutory Accounts

February 10, 2016

AOD9604 Receives GRAS Status

February 10, 2016

AOD9604 Positive in Human Bone Growth

February 10, 2016

AOD9604 Positive in Cartilage and Muscle Repair

February 10, 2016

AOD9604 Important Clarifications

February 10, 2016

Additional PolyNovo US Patent Allowed

February 10, 2016

← Newer news releases